The Effect of Ursodeoxycholic acid and N-acetyl cysteine on Lymphoblast Viability

Ali Aycicek¹, Tuba Nur Tahtakesen¹, Cengiz Bayram¹

A B S T R A C T

Aim: To investigate invitro ursodeoxycholic acid (UDCA) and N-acetyl cysteine (NAC) effect on blast cell viability in children newly diagnosed with acute lymphoblastic leukemia (ALL).

Patients and Methods: Samples were obtained from 52 newly diagnosed ALL patients aged 1 to 17 years. UDCA and NAC were added at clinically relevant concentrations (0-300 micrograms) onto 5x10⁵ cells treated at room temperature in a dark place. Untreated and treated cells were stained with 7-amino-actinomycin D (7AAD PE) and analyzed by flow cytometry.

Results: Median (interquartile range; IQR) blast percentage and incubation time were 90% (11) and 18 (1.5) hours, respectively. The dead/live blast cells ratio (7AAD+) was lower in lymphoblasts treated with all NAC concentrations than untreated controls (P < 0.001). The use of NAC was noted to, regardless of concentration, contribute to lymphoblasts viability. On the contrary, the dead/live blast cells ratio in samples treated with UDCA at the abovementioned concentrations was relatively high, suggesting the protective role for both hepatotoxicities and against leukemia. However, the difference was not statistically significant (P > 0.05). There was also no correlation between different doses of UCDA and NAC regarding blast cell viability (P > 0.232).

Conclusion: The present study showed that in vitro NAC use had a protective effect on lymphoblast viability in newly diagnosed ALL patients before starting chemotherapy. Patient-derived ALL cells can be successfully analyzed ex vivo in a short and different period without loss of blasts.

Keywords: Acute Lymphoblastic Leukemia, Children, N-acetyl cysteine, Ursodeoxycholic acid
INTRODUCTION:
All anticancer drugs can cause hepatotoxicity that may result in elevated liver enzyme levels and parenchymal cell injury (1-3). The reactions are generally dose-independent and idiosyncratic due to immunologic mechanisms. Less common are dose-dependent, predictable toxic effects of a medication or its metabolites. Chemotherapeutic agents, alone or in combination, may cause hypersensitivity reactions or direct hepatic toxicity, and altered liver function may alter drug metabolism and cause an increased risk of nonhepatic toxicity. In cancer chemotherapy, however, dosing decisions are often made based on limiting toxicity (4). Liver injury during cancer chemotherapy leads to interruption, dose reduction, or delay in cancer treatment, resulting in treatment failure and ultimately leading to cancer recurrence and poor survival. Management options in clinical practice for hepatic toxicity related to cancer treatment include discontinuing the suspected causative agent and using corticosteroids and ursodeoxycholic acid (UDCA)(5). N-acetyl cysteine (NAC) has also been shown to be effective as antioxidant adjuvant therapy in children with ALL to reduce chemo-/radiotherapy-related toxicities during the initial period of treatment (6). Despite the use of NAC and/or UDCA for hepatotoxicity development during cancer treatment, it is not known if there are any effects of these agents on blast cells. Functional studies with primary blasts from children with ALL cannot be widely used due to the difficulty of expanding ALL cells in vitro. ALL blasts are highly dependent on their in vivo environment and rapidly undergo apoptosis ex vivo. Short-term in vitro experiments have been developed to test drug sensitivity; however, their use has not been widely practiced as ALL cells in these assays are rapidly reduced, even they are not exposed to any chemotherapeutic compounds (7). The present study aimed to evaluate in vitro effects of NAC and UDCA on lymphoblasts and determine if there were any protective or apoptotic effects on leukemic cells in newly diagnosed ALL before starting chemotherapy.

Material and methods
This study included 52 children with newly diagnosed ALL between December 2018 and April 2020. Patients with ambiguous lineage ALL and patients who received glucocorticosteroids and/or other antileukemic agents were excluded from the study (8). Peripheral blood or bone marrow aspirate samples were collected into tubes without EDTA, and then were smeared on slides and stained with Wright-Giemsa stain, and whole blood analyses were performed with SYMTEX XE-2100. A pediatric hematologist made morphological identification of blast cells, and the percentage of lymphoblasts was recorded. The flow cytometry protocol was used to detect blasts, as described in detail previously (9). Cell acquisition was implemented with FacsCanto II (B.D. Biosciences) using FacsDiva V8 (B.D. Biosciences) for data analysis. Bone marrow aspiration material or whole blood sample belonging to each patient diagnosed with acute lymphoblastic leukemia in the flow cytometry laboratory were included in this study without waiting, and the experiments were started by adding UDCA and NAC doses as follows. If the sample had to be kept waiting, it was kept in the dark at room temperature (9). The stock solution was prepared at a concentration of 100 μg/3 μL and 30 μg/3 μL for UDCA and NAC study samples, respectively. And then, 0, 100, 200, 300 μg of UCDA and 0, 30, 60, 90 μg of NAC were added onto 5x10^5 cells treated for different periods (6-18 hours) at room temperature in a dark place (10). The control group, defined as NAC or UDCA untreated samples, were incubated in the same place without the addition of NAC and UDCA. Untreated and treated cells were stained with 7AAD P.E. (Becton-Dickinson, San Jose, CA, USA) according to the manufacturer’s instructions for detection of apoptosis, incubated at room temperature for 15 min before flow cytometry analysis (FACSCantoII, Becton-Dickinson, San Jose, CA, USA) with an excitation wavelength of 488 nm and a maximum emission wavelength of 677 nm. Cell acquisition was conducted, collecting per tube 30,000 events using the FacsDiva V8 (B.D. Biosciences) software for data analysis. The panel of combinations was limited to per tube of 7AAD/CD45. Viable cells (no
staining), apoptotic cells, and late-apoptotic cells were detected and quantified as a percentage of the entire cell and alive population (Figure 1, 2). The sum of apoptotic and late apoptotic cells was considered as cell death population (11). Low side scatters, moderate and bright 7AAD leukemic cells were designated as P1 gate. Absolute dead blast values were computed using the cell count of the sample (assessed with an FCM) and the relative dead estimate from the FCM analysis. Dead/cell, dead/alive, and p1/dead cell ratios were calculated for each tube’s mentioned amounts of drugs (Figure 1,2). A bivariate dot plot identified leukemic cells and normal B-lymphocytes cells as CD45 negative-dim positive cells with low side scatter. The device set-up was optimized by analyzing Calibrite beads (B.D. Biosciences) and normal peripheral B cells stained with CD3/16+56/CD45 (12). This study was approved by the institutional ethical committee (Health Sciences University, Istanbul Kanuni Sultan Suleyman Education and Research Hospital Ethical Committee; approval number: 2019/39). It was carried out according to informed consent guidelines.

**Statistical analysis**

Normality of variances was accomplished using the Kolmogorov-Smirnov test. The data were expressed as median (interquartile range) and were compared using the Mann-Whitney U, Friedman, Wilcoxon signed-rank test. Bivariate associations between variables were assessed with Pearson’s correlation test. The differences were considered statistically significant at P < 0.05. Statistical analyses were conducted using the IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp.

**RESULTS:**

There were 29 (56%) male and 23 female (44%) patients, and the median age of patients at diagnosis was 7.6 years (range 1-18 years). According to the ALLIC BFM risk stratification criteria, 3 (6%) children were classified...
as standard risk, 38 (73%) were intermediate risk, and 11 (21%) were high risk (Table 1). Forty-five (86%) children had a pre-B cell phenotype, 7 (14%) had a T cell phenotype. Median (IQR) white blood cell count, blast percentage, and incubation time for the studied samples were 70.000 (180.000)/mm3, 90% (11), and 18 (1.5) hours, respectively.

As shown in Table 2 and Figures 3-5, dead/alive, dead/cell, p1/dead ratios (7AAD+) of blasts after median 18 (1.5) hours incubation with 30 μg NAC concentration were lower than untreated controls (p < 0.001) (Figure 3-5). Similar results were obtained at 60 and 90 μg concentrations of NAC, suggesting a dose-independent effect. On the contrary, UDCA in the present concentrations relatively increased dead cell ratios (pro-oxidant) rather than contributing to the viability of the cells. However, the difference was not statistically significant (P >0.05). There was also no correlation between different doses of UCDA and NAC regarding blast cell viability (P >0.232). Results of apoptosis tests are summarized

<table>
<thead>
<tr>
<th>Age, median, IQR</th>
<th>7.6 (8.4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender, n, %</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>29 (56%)</td>
</tr>
<tr>
<td>Female</td>
<td>23 (44%)</td>
</tr>
<tr>
<td>Blast percentage of samples, median, IQR</td>
<td>90 (11)</td>
</tr>
<tr>
<td>Blast phenotype, n, %</td>
<td></td>
</tr>
<tr>
<td>Pre-B cell</td>
<td>45 (86%)</td>
</tr>
<tr>
<td>T cell</td>
<td>7 (14%)</td>
</tr>
<tr>
<td>Risk status, n, %</td>
<td></td>
</tr>
<tr>
<td>Standard</td>
<td>3 (6%)</td>
</tr>
<tr>
<td>Intermediate</td>
<td>38 (73%)</td>
</tr>
<tr>
<td>High</td>
<td>11 (21%)</td>
</tr>
<tr>
<td>The incubation time of samples, hour, IQR*</td>
<td>18 (1.5)</td>
</tr>
</tbody>
</table>

*interquartile range; P1: dead blast; NAC: N-acetyl cystein; UDCA: ursodeoxycholic acid.

Table 1. Patients characteristics.
in Table 2. There was no correlation between incubation time and apoptotic cell ratios (P > 0.05). Untreated samples incubated as without NAC or UDCA; dead defines apoptotic cells; P1, low side scatter moderate and bright 7AAD blastic cells.

**DISCUSSION**

This paper showed that patient-derived ALL cells could be successfully analyzed ex vivo in a short and different time period without loss of blasts. The detection of cell viability is critical when evaluating the physiological state of cells, such as in response to cytotoxic drugs or during the progression of neoplasia and other disease states (13). Dye exclusion is a method to identify the two cell populations. Live cells have intact membranes that exclude a variety of dyes that easily penetrate the disrupted, permeable membranes of apoptotic or non-viable cells. Flow cytometry provides a simple, rapid, cheap, reliable method to quantify viable cells in a cell suspension (13). 7-AAD is an impermeant membrane dye that assay for quantification of apoptosis with flowcytometry in peripheral blood mononuclear cells (PBMCs) and human leukemia cells (11), (14), (15). In this study, we showed that determination of cell viability with 7-AAD is critical when evaluating the physiological state of cells, such as in response to antioxidant drugs in childhood ALL. Some cancer patients or their parents use antioxidants as dietary supplements to alleviate chemotherapy-induced toxicities to increase long-term survival. However, little is known about the effectiveness and safety of antioxidant use during chemotherapy, including its interaction with chemotherapy agents (16). There is great concern about antioxidant use during cancer therapy, which may increase the viability or proliferation capacity of leukemia cells (17). Hepatic toxicity is one of the most commonly encountered side effects of childhood cancer therapy. UDCA and NAC are widely used agents in chemotherapy-related hepatic toxicity for the purpose mentioned above. Methotrexate, one of the backbone chemotherapeutic agents in childhood ALL treatment, which can induce apoptosis in hepatocytes by increasing tumor protein 53 (TP53) levels, also causes oxidative tissue injury in the liver by increasing reactive oxygen metabolites levels and lipid peroxidation. These mechanisms could be inhibited by using UDCA and NAC (6), (18). In an experimental study, Uraz et al. showed that

<table>
<thead>
<tr>
<th>UDCA, median, IQR</th>
<th>Untreated</th>
<th>100μg, 3 μL</th>
<th>200 μg, 6 μL</th>
<th>300 μg, 9 μL</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dead/Total cell</td>
<td>6.8 (15)</td>
<td>9.4 (15)</td>
<td>7.9 (13)</td>
<td>14 (9.7)</td>
<td>0.533</td>
</tr>
<tr>
<td>Dead/Alive cell</td>
<td>7.5 (22)</td>
<td>13 (21)</td>
<td>11 (17)</td>
<td>15 (21)</td>
<td>0.429</td>
</tr>
<tr>
<td>P1/Dead</td>
<td>64 (26)*</td>
<td>64 (34)</td>
<td>59 (28)</td>
<td>59 (28)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NAC, median, IQR</th>
<th>Untreated</th>
<th>30 μg (3 μL),</th>
<th>60 μg (6 μL),</th>
<th>900 μg (9 μL),</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dead/Total cell</td>
<td>8.3 (23)*</td>
<td>4.6 (12)</td>
<td>5.1 (12)</td>
<td>5.6 (17)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Dead/Alive cell</td>
<td>9.8 (37)*</td>
<td>6.2 (17)</td>
<td>6.8 (18)</td>
<td>7.5 (24)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>P1/Dead</td>
<td>73 (32)*</td>
<td>64 (22)</td>
<td>61 (33)</td>
<td>61 (31)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

*The different group.

UDCA: Ursodeoxycholic acid; NAC: N-acetyl cystein; IQR: interquartile range.

**Table 2.** Median apoptotic cell rate in study samples untreated and treated with NAC and UDCA assessed by 7AAD.
using a single dose of 20 mg/kg methotrexate for 6 days caused hepatic and/or cholestatic toxicity and hepatocyte necrosis in histopathological examination of liver tissue. By contrast, normal liver histology was observed when methotrexate was given with UDCA at 50 mg/kg. They concluded that methotrexate-induced liver parenchymal cell injury and hepatocyte necrosis could be prevented by the hepatoprotective effect of UDCA (18). However, the latter study is far from clinical use in the context of methotrexate use in childhood cancer treatment, as methotrexate is given as 36-hour or usually, 24-hour continuous infusion in the consolidation phase of treatment, while at a dose of 20-30 mg/m2 once a week in ALL maintenance therapy (19). In this regard, Bordbar et al. investigated hepatoprotective effects of UDCA in pediatric patients with ALL receiving methotrexate in the maintenance phase of treatment. There was no significant difference in patients receiving methotrexate + UDCA in this study compared to patients receiving methotrexate alone (16). In the current study, the ratio of dead/alive cells in patients treated with UDCA, although statistically not significant, was high, suggesting the protective role of UDCA for both hepatotoxocities and against leukemia. This is an in vitro study and done in ALL patients before chemotherapy. Clinical studies are needed to confirm the present study’s results. Another endpoint of our study was to address whether NAC’s protection effect on leukemic blast cells is due to its negative effect on induced-ROS production, which protects the liver and body from oxidative damage. The increase in basal ROS levels renders cancer cells highly depend-
ent on antioxidant systems and therefore vulnerable to agents that block ROS detoxifying mechanisms(20). Thus, we also assessed the dead cells/alive cells ratio regarding the effect of NAC on lymphoblasts at a different concentration compared to untreated samples without NAC. The ratio of dead cells/alive cells was lower than untreated patients, suggesting NAC’s protective effects on lymphoblasts, an undesirable effect that may lead to poor prognosis.

The pretreatment bone marrow blast burden in pediatric patients with ALL is reported to be 3x10^9. It is accepted to decrease 3 logs after the cancer cell induction treatment, and the decrease in similar rates continues in the following treatment cycles(21). Despite achieving morphological and molecular remission even in maintenance, a significant number of cells may be present in the body responsible for subsequent relapse (22). Therefore, factors leading to treatment delay have prognostic significance for achieving a good response to chemotherapy and long-term survival. Thus, elevated liver function tests, one of the most common reasons for the chemotherapy interruption, should not indicate treatment adaptation and/or the initiation of antioxidant agents such as NAC and UDCA if liver function is normal. (2).

There are some limitations to this study. It was an in vitro study, samples were studied in a dark place at room temperature, and drug doses were determined by considering therapeutic doses and the amount of body fluid composition. However, the current study is the first to demonstrate the protective effect of NAC use on lymphoblast viability that may cause ALL treatment failure and poor survival. Also, patient-derived ALL cells can be successfully analyzed ex vivo within a short period of time without loss of blasts.

**Author contributions**

B.A.A. designed the study, developed the flow cytometry assays, performed the statistical analysis, analyzed the data, and wrote the manuscript. T. N. T. performed flow cytometry assay and data acquisition; C. B. revised and edited the article.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest concerning this article’s research, authorship, and/or publication.

**Funding**

The author(s) received no financial support for this article’s research, authorship, and/or publication.

**ORCID ID**

Ali Aycicek: https://orcid.org/0000-0001-8951-4750

**REFERENCES**

spectrum of application compared with other techniques. Blood 1996;87:2244-2251.


